关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 湖北共同药业股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开第 三届董事会第三次会议、第三届监事会第三次会议，审议通过了《关于回购公司股 份方案的议案》，同意公司使用自有资金及股票回购专项贷款资金以集中竞价交易 方式回购公司已发行的股份，用于股权激励或员工持股计划。本次回购总金额不低 于人民币 2,000 万元（含）且不超过人民币 3,000 万元（含），回购价格不超过 23.84 元/股，具体回购资金总额以回购期满时实际回购股份使用的资金总额为准，回购期 限为董事会审议通过该回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 2 月 20 日、2025 年 2 月 26 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公告编号： 2025-006）、《回购报告书》（公告编号：2025-008）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 ...

Core Viewpoint - The company reported steady revenue growth in Q1 2025, but profit performance was negatively impacted by increased expenses [2] Financial Performance - In Q1 2025, the company achieved revenue of 139 million yuan, a year-on-year increase of 13.90% [2][4] - The net profit attributable to shareholders was 1.08 million yuan, a year-on-year decrease of 69.50% [2][4] - The non-recurring net profit was 1.34 million yuan, down 61.42% year-on-year [2] - The gross margin improved to 24.24%, an increase of 2.67 percentage points year-on-year [2] - The net margin was -0.55%, a decline of 2.92 percentage points year-on-year [2] Cost and Investment Insights - The decline in net profit was primarily due to increased R&D expenses from the subsidiary Huahai, which rose by 4.39 million yuan year-on-year [2] - Financial expenses increased by 7.49 million yuan year-on-year due to the cessation of capitalizing interest on convertible bonds after the completion of fundraising projects [2] Capacity Expansion - As of March 31, 2025, the company's total fixed assets amounted to 1.13 billion yuan, an increase of 927 million yuan compared to the same period in 2024, expanding the total scale by approximately five times [2] - The company has officially put into production the fundraising project "Production Construction Project of Progesterone and Intermediate BA" and is enhancing the construction of the Huahai joint raw material drug project and steroid industry chain upgrade project [2] Share Buyback Program - The company plans to repurchase shares using its own funds and a special loan for share buybacks, with 10% from its own funds and 90% from the loan [3] - The total repurchase amount will be no less than 20 million yuan and no more than 30 million yuan, with a maximum repurchase price of 23.84 yuan per share [3] - As of March 31, 2025, the company had repurchased 120,000 shares, accounting for 0.10% of the total share capital, with a total transaction amount of 1.92 million yuan [3] Investment Outlook - The company’s capacity is expected to be gradually released, and profitability is anticipated to recover with increased capacity utilization [4] - Revenue forecasts for 2025, 2026, and 2027 are 617 million yuan, 741 million yuan, and 889 million yuan, respectively, with net profits projected at -31 million yuan, -15 million yuan, and 53 million yuan [4] - Corresponding PE ratios for 2026 and 2027 are estimated at 121X and 33X, respectively, with a continued "buy" rating [4]

| 编制单位：湖北共同药业股份有限公司 | 2025 年 03 月 31 日 | 单位：元 | | --- | --- | --- | | 项目 | 期末余额 | 期初余额 | | 流动资产： | | | | 货币资金 | 157,140,791.92 | 141,181,205.23 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 1,010.63 | 1,010.63 | | 衍生金融资产 | | | | 应收票据 | 22,515,024.53 | 15,969,258.05 | | 应收账款 | 212,208,690.54 | 188,668,396.08 | | 应收款项融资 | 6,061,995.64 | 9,623,992.21 | | 预付款项 | 17,908,414.10 | 10,721,612.30 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 3,674,702.79 | 2,052,867.78 | | 其中：应收利息 | | | | 应收股利 | | | | 买入返售金融资 ...

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-030 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 第三届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"）第三届监事会第五次会议于 2025 年 4 月 28 日在公司会议室以现场结合通讯表决的方式召开。会议通知及材料于 2025 年 4 月 18 日以电话、微信等通讯的方式送达。会议由公司监事会主席蒋建军主 持，会议应到监事 3 人，实际参会监事 3 人。 会议的召开符合《中华人民共和国公司法》《湖北共同药业股份有限公司章程》 《湖北共同药业股份有限公司监事会议事规则》的规定，会议决议合法有效。 二、监事会会议审议情况 经全体监事认真审议并表决，会议审议通过了以下议案： 审议通过《关于〈公司 2025 年第一季度报告〉的议案》 经审议，监事会认为：董事会编制和审核《2025 年第一季度报告》的程序符合 法律 ...

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-029 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 第三届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 经审议，董事会认为：公司《2025 年第一季度报告》的编制和审核符合相关法 律法规和中国证券监督管理委员会与深圳证券交易所的相关规定，报告内容真实、 准确、完整，不存在任何虚假记载、误导性陈述或重大遗漏。 本议案中的财务报告部分已经公司董事会审计委员会全体成员审议通过。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《2025 年第 一季度报告》（公告编号：2025-031）。 表决结果：同意 7 票，反对 0 票，弃权 0 票。本议案获得通过。 1 一、董事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"）第三届董事会第六次会议于 2025 年 4 月 28 日在公司会议室以现场结合通讯表决的方式召开。会议通知及材料于 2025 ...

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 系祖斌 | 914.18 | 11.92 | 不变 | | 丹江口市共同创新投资合伙企业(有限合伙) | 510.65 | 6.66 | 不变 | | 李明磊 | 343.13 | 4.48 | 不变 | | 浙江华海药业（600521）股份有限公司 | 311.79 | 4.07 | 不变 | | 湖北高金生物科技创业投资基金合伙企业(有限合 伙) | 161.32 | 2.10 | 不变 | | 张欣 | 140.09 | 1.83 | 不变 | | 深圳市佳俊丽豪投资发展有限公司 | 136.67 | 1.78 | 不变 | | 汪善友 | 99.01 | 1.29 | -5.74 | | 国泰佳泰股票专项型养老金产品-招商银行股份有限 公司 | 80.47 | 1.05 | -0.92 | | 李洪强 | 46.55 | 0.61 | 新进 | | 较上个报告期退出前十大股东有 | | | | | 李光明 | 87 ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥139,216,213.10, representing a 13.90% increase compared to ¥122,227,974.51 in the same period last year[6] - Net profit attributable to shareholders decreased by 69.50% to ¥1,082,077.92 from ¥3,547,307.04 year-on-year[6] - The net profit for the period was a loss of ¥762,780.33, contrasting with a profit of ¥2,893,085.07 in the previous period[20] - The weighted average return on equity decreased to 0.12% from 0.37% year-on-year, reflecting a decline in profitability[6] - The company reported a basic earnings per share of ¥0.01, down from ¥0.03 in the previous period[20] Cash Flow - The net cash flow from operating activities was negative at -¥28,774,281.53, worsening by 18.79% compared to -¥24,222,072.61 in the previous year[6] - Cash flow from operating activities showed a net outflow of ¥28,774,281.53, compared to a net outflow of ¥24,222,072.61 in the previous period[21] - The cash inflow from operating activities totaled ¥107,168,250.73, down from ¥157,223,568.99 in the previous period[21] - Net cash flow from investing activities was -¥82,126,429.98, a decrease of 41.28% compared to Q1 2023, primarily due to increased cash payments for fixed assets[13] - Net cash flow from financing activities for Q1 2024 is 96,023,008.50 yuan, an increase of 112.04% compared to Q1 2023, mainly due to increased bank borrowings[13] Assets and Liabilities - Total assets grew by 4.43% to ¥2,913,552,562.84 from ¥2,789,880,328.86 at the end of the previous year[6] - Total current assets as of March 31, 2025, amount to 872,425,299.25 yuan, up from 769,997,377.12 yuan at the beginning of the period[17] - Total liabilities increased to ¥1,901,488,230.91 from ¥1,775,238,273.87, representing a growth of 7.1%[18] - The total liabilities include short-term borrowings of 291,238,917.77 yuan, slightly down from 294,303,069.17 yuan[17] - The total equity decreased slightly to ¥1,012,064,331.93 from ¥1,014,642,054.99, a decline of 0.3%[18] Research and Development - R&D expenses increased by 46.20% to ¥13,895,986.99 from ¥9,505,034.39 year-on-year, primarily due to new R&D activities by subsidiary Huahai[11] - Research and development expenses increased significantly to ¥13,895,986.99, compared to ¥9,505,034.39, marking a growth of 46.5%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,915, with no preferred shareholders having restored voting rights[12] - The largest shareholder, Xi Zubin, holds 31.72% of shares, totaling 36,567,000 shares, with 27,425,250 shares under lock-up[12] - The company has a total of 38,614,444 shares under lock-up, with no shares released during the reporting period[15] Financial Expenses and Losses - The financial expenses surged by 259.48% to ¥10,371,045.89, mainly due to the cessation of capitalization of project loans and convertible bond interest[11] - The company incurred financial expenses of ¥10,371,045.89, significantly higher than ¥2,885,024.73 in the previous period, indicating an increase of 260.5%[20] - The company recorded a loss from asset disposal of ¥1,572,500.23, attributed to the disposal of fixed assets during the period[11] Other Financial Metrics - The company reported a significant increase in prepayments by 67.03% to ¥17,908,414.10, indicating higher advance payments for goods[9] - The cash and cash equivalents at the end of the reporting period amount to 157,140,791.92 yuan, an increase from 141,181,205.23 yuan[16] - The ending cash and cash equivalents balance was $85.30 million, an increase from $59.43 million year-over-year[22] - Cash outflow for debt repayment was $33.02 million, down from $38.62 million, indicating reduced debt servicing costs[22] - Cash paid for dividends and interest was $2.90 million, slightly down from $3.09 million, reflecting stable shareholder returns[22] Accounting and Reporting - The first quarter report was not audited, which may affect the reliability of the financial data presented[23] - The company will implement new accounting standards starting in 2025, which may impact future financial reporting[24]

Group 1 - Shenjian Co., Ltd. reported a net profit of 33.65 million yuan for 2024, a year-on-year increase of 32.29%, with a proposed cash dividend of 0.5 yuan per 10 shares [1] - Jingce Electronics experienced a net loss of 97.60 million yuan in 2024, transitioning from profit to loss, despite a revenue increase of 5.59% to 2.565 billion yuan [1] - Jingwei Co., Ltd. reported a net profit of 35.54 million yuan for 2024, a decrease of 36.76%, with a proposed cash dividend of 1.00 yuan per 10 shares [1][2] Group 2 - Minsheng Health achieved a net profit of 91.83 million yuan in 2024, a year-on-year increase of 7.24%, with a proposed cash dividend of 1.00 yuan per 10 shares [2] - Zhongshe Co., Ltd. reported a net profit of 10.16 million yuan for 2024, a decline of 76.24%, with a proposed cash dividend of 0.2 yuan per 10 shares [3] - Keyuan Smart reported a net profit of 252 million yuan for 2024, a year-on-year increase of 56.64%, with a proposed cash dividend of 0.4 yuan per 10 shares [4] Group 3 - Beilu Pharmaceutical reported a net profit of 14.54 million yuan for Q1 2025, a year-on-year increase of 26.13%, with revenue of 283 million yuan [5] - Wangsu Technology achieved a net profit of 192 million yuan for Q1 2025, a year-on-year increase of 38.54%, with revenue of 1.235 billion yuan [6] - Keyuan Pharmaceutical reported a net profit of 23.08 million yuan for Q1 2025, a year-on-year increase of 7.25%, despite a revenue decline of 23.98% [7] Group 4 - Guangting Information reported a net profit of 24.03 million yuan for Q1 2025, turning from loss to profit, with revenue of 134 million yuan [9] - Zhaori Technology reported a net loss of 1.23 million yuan for Q1 2025, with revenue of 35.23 million yuan [11] - Huakai Yibai reported a net loss of 15.09 million yuan for Q1 2025, despite revenue growth of 35.08% to 2.292 billion yuan [13] Group 5 - Xinhongye reported a net profit of 34.43 million yuan for Q1 2025, a year-on-year increase of 20.43%, with revenue of 755 million yuan [15] - Huning Co., Ltd. reported a net profit of 3.61 million yuan for Q1 2025, a year-on-year decrease of 45.68%, with revenue of 64.51 million yuan [16] - Camel Co., Ltd. reported a net profit of 237 million yuan for Q1 2025, a year-on-year increase of 51.89%, with revenue of 4.136 billion yuan [17] Group 6 - Hengtong Co., Ltd. reported a net profit of 42.55 million yuan for Q1 2025, a year-on-year increase of 51.62%, with revenue of 313 million yuan [19] - Changqing Technology reported a net profit of 35.38 million yuan for Q1 2025, a year-on-year decrease of 23.80%, with revenue of 246 million yuan [21] - Libaba Co., Ltd. reported a net profit of 34.72 million yuan for Q1 2025, a year-on-year increase of 9.91%, with revenue of 419 million yuan [22] Group 7 - Shouxiangu reported a net profit of 58.37 million yuan for Q1 2025, a year-on-year decrease of 24.32%, with revenue of 171 million yuan [24] - Bojun Technology announced a stock issuance application accepted by the Shenzhen Stock Exchange [24] - Dayou Energy announced the full resumption of production at its Gengcun coal mine, with an annual production capacity of 3.6 million tons [25] Group 8 - Deyang Co., Ltd. successfully acquired land use rights for industrial land in Ningbo for 45.80 million yuan [27] - Tianyu Pharmaceutical's subsidiary received a drug registration certificate for an injectable product [29] - Xingwang Yuda signed a strategic cooperation agreement with the Jilin Province Bionic Robot Innovation Center [30] Group 9 - Lifang Pharmaceutical received approval for clinical trials of a new drug [32] - Zai Sheng Technology reported a net profit of 33.56 million yuan for Q1 2025, a year-on-year increase of 3.69%, with revenue of 324 million yuan [34] - Jinxin Technology reported a net profit of 319,920 yuan for Q1 2025, turning from loss to profit, with revenue of 563 million yuan [36] Group 10 - Huayin Electric reported a net profit of 75.67 million yuan for Q1 2025, a year-on-year increase of 894.61%, with revenue of 2.307 billion yuan [37] - Xinghua Co., Ltd. reported a net loss of 95.51 million yuan for Q1 2025, with revenue of 840 million yuan [38] - Heren Technology reported a net loss of 384,410 yuan for Q1 2025, with revenue of 78.40 million yuan [40] Group 11 - Fenda Technology reported a net profit of 40.45 million yuan for Q1 2025, a year-on-year increase of 84.07%, with revenue of 760 million yuan [41] - Tongda Co., Ltd. reported a net profit of 25.49 million yuan for 2024, a year-on-year decrease of 69.15%, with revenue of 6.201 billion yuan [43] - Zhonghe Holdings reported a net profit of 283 million yuan for 2024, a year-on-year decrease of 54.69%, with a proposed cash dividend of 0.3 yuan per 10 shares [44] Group 12 - Jiantou Energy reported a net profit of 531 million yuan for 2024, a year-on-year increase of 181.59%, with a proposed cash dividend of 1.3 yuan per 10 shares [44] - Guanghua Technology reported a net loss of 205 million yuan for 2024, with revenue of 2.589 billion yuan [45] - Huajin Technology reported a net profit of 29.26 billion yuan for 2024, a year-on-year increase of 8.1%, with a proposed cash dividend of 9 yuan per 10 shares [46] Group 13 - Yingke Medical reported a net profit of 1.465 billion yuan for 2024, a year-on-year increase of 282.63%, with a proposed cash dividend of 1.00 yuan per 10 shares [46] - Solar Energy reported a net profit of 1.225 billion yuan for 2024, a year-on-year decrease of 22.38%, with a proposed cash dividend of 0.56 yuan per 10 shares [46] - Dongfang Electric reported a net profit of 318 million yuan for 2024, a year-on-year decrease of 50.62%, with a proposed cash dividend of 0.32 yuan per 10 shares [47] Group 14 - Tianneng Heavy Industry reported a net loss of 262 million yuan for 2024, with revenue of 3.273 billion yuan [48] - Gangyan High-tech reported a net profit of 249 million yuan for 2024, a year-on-year decrease of 22.08%, with a proposed cash dividend of 1.00 yuan per 10 shares [48] - Shihua Machinery reported a net profit of 96.88 million yuan for 2024, a year-on-year increase of 5.35%, with revenue of 8.037 billion yuan [49] Group 15 - Gongtong Pharmaceutical reported a net loss of 27.59 million yuan for 2024, with revenue of 537 million yuan [51] - Zhongjing Electronics reported a net loss of 87.43 million yuan for 2024, with revenue of 2.932 billion yuan [53] - Yudai Development reported a net loss of 114 million yuan for 2024, with revenue of 388 million yuan [55] Group 16 - Zhenhua Technology reported a net profit of 970 million yuan for 2024, a year-on-year decrease of 63.83%, with a proposed cash dividend of 1.8 yuan per 10 shares [56] - Jierong Technology reported a net loss of 298 million yuan for 2024, with revenue of 1.357 billion yuan [58] - Changgao Electric New reported a net profit of 252 million yuan for 2024, a year-on-year increase of 45.66%, with a proposed cash dividend of 0.8 yuan per 10 shares [60] Group 17 - Shibao Detection announced a plan to acquire 81% of Zhonghuan Lianshu for 52.65 million yuan [61] - Jiangsu Boyun announced a plan to reduce its shareholding by up to 3% [62] - Jingfeng Mingyuan announced a plan to acquire 100% of Yichong Technology for 3.283 billion yuan [63]

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-027 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、会议召集人：湖北共同药业股份有限公司董事会。2025 年 4 月 22 日，湖北 共同药业股份有限公司（以下简称"共同药业"或"公司"）召开第三届董事会第 五次会议，审议通过了《关于召开 2024 年年度股东大会的议案》。 3、会议召开的合法、合规性：公司董事会决议召开本次股东大会符合有关法律、 行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： 现场会议召开时间：2025 年 5 月 14 日（星期三）下午 14:00 （2）公司董事、监事和高级管理人员。 （3）公司聘请的见证律师。 8、现场会议地点：湖北省襄阳市樊城区卧龙大道江山南路环球金融城 1 号楼 3 ...

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-017 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 第三届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"）第三届监事会第四次会议于 2025 年 4 月 22 日在公司会议室以现场方式召开。会议通知及材料于 2025 年 4 月 11 日以现场送达的方式送达。会议由公司监事会主席蒋建军主持，会议应到监事 3 人， 实际参会监事 3 人。 会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"）、《湖 北共同药业股份有限公司章程》（以下简称"《公司章程》"）、《湖北共同药业 股份有限公司监事会议事规则》的规定，会议决议合法有效。 二、监事会会议审议情况 经全体监事认真审议并表决，会议审议通过了以下议案： （一）审议通过《关于〈公司 2024 年年度报告〉及其摘要的议案》 经审议，监事会认为：董事会编制和 ...